Sr. Director of R&D
Covaris, MA, United States
Dr. Thomann (Senior Director R&D) joined Covaris in Fall 2016 to lead the R&D department. He is intimately familiar with the potential and the vast opportunities The Company’s Adaptive-focused (AFA) technology has to offer. During his tenure, he was leading the development of kits and applications for extraction and isolation of biomolecules from eukaryotic and prokaryotic cells/tissues (fresh/frozen, culture), from preserved FFPE samples (truXTRAC portfolio) and other difficult to process specimens, such as whole desiccated blood (e.g., truCOLLECT).
During his previous assignment at T2Biosystems, Inc. (Lexington, MA), he was tasked with the development of sensitive and highly specific multiplexed PCR-based assays for clinical detection and identification of pathogens in whole blood w/o need for blood culture. This culminated in the FDA approval and commercialization of the T2Bacteria assay.
Previously, at NetBio (now ANDE Corporation, Waltham, MA), he focused on development of highly multiplexed PCR-based assays compatible with the Company’s fully integrated microfluidic system. Assays were developed to detect and identify Select Biological Agents as well STD-relevant bacterial species.
Earlier Dr. Thomann was involved in the human genome project (Genome Therapeutics, Waltham, MA) where he developed an ‘industrialized’ shotgun library construction process and contributed significantly to automating the sequencing pipeline for pharmacogenetics/genomics.
Dr. Thomann received his Ph.D, in Biochemistry /M.S. Diploma in Organic Chemistry from the Julius-Maximilians-University (Würzburg, Bavaria) and spent time as a Postdoctoral Fellow and Associate Research Scientist at Yale University (MB&B, Prof. Söll Lab).
Disclosure information not submitted.
Tuesday, February 8, 2022
11:30 AM – 12:30 PM